At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Remetinostatdrug
Likely dose
Remetinostat applied topically 3 times daily for 6 weeksAI-extracted
Key inclusion· 2
- ✓At least one BCC lesion >1 cm (or >5 mm) in non-cosmetically sensitive site(s)
- ✓Willing to apply topical remetinostat 3 times daily for 6 weeks
Key exclusion· 11
- ✕Taking medications known to interact with HDAC inhibitors (e.g., valproate, anticoagulants)
- ✕Taking medications affecting hedgehog signaling pathway (e.g., itraconazole)
- ✕Within past 6 months: topical or systemic therapies interfering with study evaluation including glucocorticoids, retinoids, alpha hydroxy acids (>5%), 5-fluorouracil, imiquimod, or itraconazole
- ✕Systemic chemotherapy or hedgehog signaling inhibitors within 60 days of starting study medication
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-Label, Single-Arm Trial of the Efficacy of Topical Remetinostat on Basal Cell Carcinoma in Patients
In Brief
A Phase 2 clinical trial evaluating Remetinostat for Skin Basal Cell Carcinoma. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This phase 2 trial studies how well remetinostat works in treating patients with skin basal cell cancer. Remetinostat may slow the growth of basal cell cancer cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Basal Cell Carcinoma
CountriesUnited States
CollaboratorsMedivir, National Institutes of Health (NIH), American Skin Association
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartJul 2018
Primary CompletionJul 2020
Study CompletionDec 2020
TodayJul 2026
First PostedJun 8, 2017
Enrollment StartJul 7, 2018
Primary CompletionJul 7, 2020
Study CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 9.1 years ago
Interventions
Remetinostatdrug
Applied topically under bandage occlusion